Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings of American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $46.303 per ADS
- Transaction Date: July 5, 2012
- Transaction Type: Re-investment of dividends paid to shareholders
Material Changes
The filing details an increase in personal holdings for specific directors and connected persons due to dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Directors and PDMRs increased their ADS holdings on July 5, 2012, via dividend re-investment.
- Key individuals involved include Dr. M M Slaoui (708.620 ADSs), Mrs. D P Connelly (344.050 ADSs), and Dr. D Pulman (443.737 ADSs).
- Dr. K Slaoui is listed as a connected person with an increase of 12.719 ADSs.
- The company was advised of these transactions on July 12, 2012.